Eli Lilly and Co. has announced a manufacturing expansion in Indianapolis that will add 100 new high-skilled jobs to its operations.
The company is reportedly planning to pump $400 million into its Lilly Technology Center campus to boost its capacity for diabetes treatments. Lilly produces insulin at the facility along with 10 other non-insulin diabetes medications. The new investment will add on to the $2 billion the company has injected into its diabetes manufacturing capabilities since 2012.
The new investment will target syringe-filling, packaging and device assembly operations and support the company’s continued focus on next-generation manufacturing capabilities such as automation and robotics.
Lilly, along with the few other companies that produce insulin, has been the target of criticism for the high price of the life-saving drug. But the company is now planning to launch a generic version of its insulin treatment, Humalog.
Read the Indy Star report.
